OCUL
Price
$8.51
Change
-$0.00 (-0.00%)
Updated
Feb 4, 03:08 PM (EDT)
Capitalization
1.81B
33 days until earnings call
Intraday BUY SELL Signals
RYTM
Price
$106.22
Change
-$2.07 (-1.91%)
Updated
Feb 4, 03:16 PM (EDT)
Capitalization
7.23B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

OCUL vs RYTM

Header iconOCUL vs RYTM Comparison
Open Charts OCUL vs RYTMBanner chart's image
Ocular Therapeutix
Price$8.51
Change-$0.00 (-0.00%)
Volume$2.66K
Capitalization1.81B
Rhythm Pharmaceuticals
Price$106.22
Change-$2.07 (-1.91%)
Volume$100
Capitalization7.23B
OCUL vs RYTM Comparison Chart in %
OCUL
Daily Signal:
Gain/Loss:
RYTM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
OCUL vs. RYTM commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a StrongBuy and RYTM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (OCUL: $8.51 vs. RYTM: $108.29)
Brand notoriety: OCUL and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 152% vs. RYTM: 76%
Market capitalization -- OCUL: $1.81B vs. RYTM: $7.23B
OCUL [@Biotechnology] is valued at $1.81B. RYTM’s [@Biotechnology] market capitalization is $7.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, RYTM is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 6 bullish TA indicator(s).

  • OCUL’s TA Score: 4 bullish, 6 bearish.
  • RYTM’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а -21.57% price change this week, while RYTM (@Biotechnology) price change was +2.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

OCUL is expected to report earnings on Mar 09, 2026.

RYTM is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($7.23B) has a higher market cap than OCUL($1.81B). RYTM YTD gains are higher at: 1.168 vs. OCUL (-29.901). RYTM has higher annual earnings (EBITDA): -169.02M vs. OCUL (-233.54M). RYTM has more cash in the bank: 416M vs. OCUL (345M). RYTM has less debt than OCUL: RYTM (4.14M) vs OCUL (77M). RYTM has higher revenues than OCUL: RYTM (174M) vs OCUL (55.8M).
OCULRYTMOCUL / RYTM
Capitalization1.81B7.23B25%
EBITDA-233.54M-169.02M138%
Gain YTD-29.9011.168-2,560%
P/E RatioN/AN/A-
Revenue55.8M174M32%
Total Cash345M416M83%
Total Debt77M4.14M1,860%
FUNDAMENTALS RATINGS
OCUL vs RYTM: Fundamental Ratings
OCUL
RYTM
OUTLOOK RATING
1..100
618
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
10024
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6544
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for RYTM (79) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (24) in the Biotechnology industry is significantly better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew significantly faster than OCUL’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as RYTM (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (44) in the Biotechnology industry is in the same range as OCUL (65) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew similarly to OCUL’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULRYTM
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 21 days ago
78%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 20 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signal:
Gain/Loss:
RYTM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCGEX8.750.10
+1.16%
VALIC Company I Emerg Economies
TIRHX17.890.04
+0.22%
Nuveen Real Estate Sec Sel I
ITETX10.61-0.01
-0.09%
VY® T. Rowe Price Equity Income S2
JEUIX17.95-0.20
-1.10%
Janus Henderson Global Sust Eq I
PGORX67.79-1.19
-1.73%
Putnam Large Cap Growth R

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with WVE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-6.99%
WVE - OCUL
54%
Loosely correlated
+2.01%
NRIX - OCUL
53%
Loosely correlated
-1.76%
NUVL - OCUL
53%
Loosely correlated
+2.12%
ERAS - OCUL
53%
Loosely correlated
-0.24%
DYN - OCUL
52%
Loosely correlated
+1.07%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with OCUL. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-0.64%
OCUL - RYTM
41%
Loosely correlated
-6.99%
XENE - RYTM
39%
Loosely correlated
+1.62%
TARS - RYTM
39%
Loosely correlated
+1.41%
CRNX - RYTM
39%
Loosely correlated
+1.24%
VIR - RYTM
39%
Loosely correlated
-0.39%
More